NCT05639933 - Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Acneiform Eruption Due to ChemicalXerosis CutisParonychia

Interventions

DRUG

HT-001 2% Topical Gel

Topical gel, 2% active

DRUG

HT-001 1% Topical Gel

Topical gel, 1% active

DRUG

HT-001 0.5% Topical Gel

Topical gel, 0.5% active

DRUG

HT-001 Placebo

Topical gel, vehicle gel

Trial Locations (8)

10467

RECRUITING

Montefiore Medical Center, The Bronx

11042

RECRUITING

Northwell Physician Partners Dermatology, New Hyde Park

11501

RECRUITING

NYU Langone Health, Mineola

20037

RECRUITING

The George Washington University Medical Faculty Associates, Washington D.C.

77030

RECRUITING

MD Anderson Cancer Center, Houston

92612

RECRUITING

UCI Health - CIACC, Irvine

92868

RECRUITING

UC Irvine - Chao Family Cancer Center, Orange

02215

RECRUITING

Dana Farber Cancer Institute, Boston